Results 31 to 40 of about 59,932 (250)

Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants [PDF]

Clinical and Translational Science
Remdesivir is an intravenous antiviral approved worldwide for the treatment of COVID‐19 in adults and children. Remdesivir, as a prodrug inhibitor of RNA polymerase, undergoes intracellular activation to form the active metabolite along with 2 inactive ...
Jack Chang, Aryun Kim, Rita Humeniuk, Naveed A. Shaik, Helen Winter, Chi‐Chi Peng, Deqing Xiao, Mazin Abdelghany, Joe Llewellyn, Santosh Davies, Kandace Golden, Shuguang Chen, Robert H. Hyland, Luzelena Caro   +13 more
doaj   +2 more sources

Remdesivir

Reactions Weekly, 2022
  +16 more sources

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Lancet, The, 2020
Guan-Hua Du, Jianping Zhao, Yang Jin
exaly   +2 more sources

The impact of remdesivir on SARS-CoV-2 evolution in vivo

JCI Insight
The impact of remdesivir on SARS-CoV-2 diversity and evolution in vivo has remained unclear. In this single-center, retrospective cohort study, we assessed SARS-CoV-2 diversification and diversity over time in a cohort of hospitalized patients who did or
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, Alexandre Machado Carvalho, Maria Francesca R. Agnes, Arghavan Alisoltanidehkordi, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist   +8 more
doaj   +2 more sources

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Viruses, 2019
Remdesivir (GS-5734) is a 1′-cyano-substituted adenosine nucleotide analogue prodrug that shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently under clinical development for the treatment of Ebola virus disease (
Joy Y Feng, Danielle P Porter, Matthias Götte   +2 more
exaly   +2 more sources

Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era. [PDF]

Clinical Infectious Diseases
BACKGROUND: Patients with immunocompromising conditions are at increased risk for coronavirus disease 2019 (COVID-19)-related hospitalizations and deaths.
Amin, Alpesh, Berry, Mark, Chandak, Aastha, Chima-Melton, Chidinma, Gottlieb, Robert, Kalil, Andre, Mozaffari, Essy, Sax, Paul   +7 more
core   +2 more sources

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Antiviral Research, 2020
Sin Fun Sia, Kenrie Pui Yan Hui, Xuhui Huang   +2 more
exaly   +2 more sources

Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals. [PDF]

Clinical Infectious Diseases
BACKGROUND: Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients.
Ahuja, Neera, Amin, Alpesh, Berry, Mark, Casciano, Roman, Chandak, Aastha, Doi, Yohei, Kolditz, Martin, Loubet, Paul, Mozaffari, Essy, Müller, Veronika, Sax, Paul   +10 more
core   +2 more sources

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Life Sciences, 2020
Abdo A. Elfiky
exaly   +2 more sources

Clinical Outcomes of Remdesivir in Moderate and Severe Cases of COVID-19: A Retrospective Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: Remdesivir is a nucleotide analogue prodrug that perturbs viral replication. Remdesivir has been used in various trials previously for the treatment of Coronavirus Disease 2019 (COVID-19).
Ruth Priya Senthiappan, Archana A Dambal, Mohan Kashinkunti, Kiran R Aithal, Rajendra Kumar Parakh, Bhargav Vuppumalla   +5 more
doaj   +1 more source